000			02972cam a2200313 a 4500
003			EG-GiCUC
008			180806s2017 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.32.M.Sc.2017.Es.E
100	0		_aEsraa Mohammed Seif Eldin
245	1	0	_aEvaluation of treatment adherence in patients with Behçet{u2019}s disease: its relation to disease parameters and patients' beliefs about medications / _cEsraa Mohammed Seif Eldin ; Supervised Hania Salah Mohammed Zayed , Basma Mohammed Medhat Ali
246	1	5	_aتقييم مدى الالتزام فى مرضى بهجت : _bعلاقته بمقاييس المرض و معتقدات المرضى تجاه العلاج الدوائى
260			_aCairo : _bEsraa Mohammed Seif Eldin , _c2017
300			_a192 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Rheumatology and Rehabilitation
520			_aAim: Behçet{u2019}s disease (BD) is a chronic systemic vasculitis, in which adherence to treatment is essential for successful management.This study evaluated medication adherence in BD and factors potentially affecting it. Patients and Methods: Sixty-seven patients with BD were included. Patients were interviewed to assess a) socioeconomic status using the family socioeconomic status questionnaire (SES) for health research in Egypt b) treatment adherence using the compliance questionnaire of rheumatology (CQR), c) beliefs about medications through the Beliefs about Medication Questionnaire (BMQ), and d) quality of life using the short form 36 (SF36). Results: The study included 67 patients including 57 (85%) male. The mean age of onset was 35.1±9.27 years, while the mean disease duration was 129±91 months. The median of the CQR was 70; upon which the patients were divided into adherent [N=38 (57%)] and non-adherent groups [N=29 (43%)]. Apart from beliefs about medications, there were no statistically significant differences between the two groups. Predictors for medication adherence were; the score of the health care domain of the SES (Ý=0.38; P=0.004), necessity beliefs of the BMQ (Ý=0.82; P=0.002) and emotional wellbeing and social functioning scores of the SF 36 (Ý=0.3 and 0.38; P=0.03 and 0.006, respectively), while neurological involvement and occurrence of side effects predicted non-adherence to treatment (Ý=-0.29 and -0.35; P=0.028 and 0.009, respectively). Conclusions: The frequency of adherence to treatment in BD is suboptimal. Several predictors of adherence were identified
530			_aIssued also as CD
653		4	_aAdherence
653		4	_aBehçet{u2019}s disease
653		4	_aCompliance
700	0		_aBasma Mohammed Medhat Ali , _eSupervisor
700	0		_aHania Salah Mohammed Zayed , _eSupervisor
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c66960 _d66960